HLA and Hodgkin's disease: reply to Taylor and Gokhale
In the September 1996 issue of Leukemia, we commented on and incidentally, mice do not have an expressed homologue of the HLA-DP locus. a paper by Taylor et al previously published in the journal. 1, 2 Our main concern was the lack of statistical evaluation. In a Also in childhood ALL, we did not find a significant increase in the genotype frequencies in the whole group of following issue, a reply by two of the authors was published, 3 in which instead of replying to the main criticism on the lack 63 patients (17.5 vs 13.6%). 6 However, the homozygosity rates were different between boys and girls (27.7 vs 3.7%, of any significant increase in their report, Gokhale and Taylor chose to attempt to invalidate our unpublished results in P = 0.01) yielding a relative risk of 3.29 (95%, CI = 1.37-7.90) for boys homozygous for DR53 to develop common ALL (33.3 Hodgkin's disease as well as our previous findings in other hemopoietic malignancies.
vs 13.6%, P = 0.008). These findings have now been confirmed in an updated group of 84 patients. 11 Based on the Dorak et al are still persuaded that homozygosity for HLA-DR53 is the most consistent association in hemopoietic maligmolecular mimicry between HLA-DR53 antigen and viral proteins, 12 and this gender effect, we have been able to propose nancies as it has been shown in three leukemias (CML, ALL, CLL) in three different populations by molecular analysis. [4] [5] [6] a model which might be relevant in the development (not etiology) of childhood ALL.
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Also in AML, an HLA-DR53 association was noted in a study that used a specific monoclonal antibody. 7 In CLL, an HLAHomozygosity for HLA-DR53 precisely means homozygosity for the HLA-DRB4‫10ء‬ allele therefore mapping the suscep-DR53 association was previously reported in another British study. 8 In the first molecular HLA association study on leuketibility around the DRB4 locus. We did check the relevance of the HLA-DRB1 locus by scientific methods both in CML mia, we typed 112 patients and 432 local controls at 10 MHC loci to have a holistic view of the HLA complex and to avoid and CLL and did not find a stronger association with it. There is no reason to discuss the meaning of heterozygosity for spurious associations due to linkage disequilibrium. 4 By conventional analysis, there was no difference in the homozygos-DRB1 alleles as it is not the susceptibility locus. As discussed above there is enough reason to believe HLA-DR53 is the susity rates between patients and local controls (11.6 vs 13.4%, respectively). Most researchers in this field would have conceptibility allele in hemopoietic malignancies and this association may be HVR sequence-related. The seven consecutive cluded a lack of association. However, the oldest patient homozygous for HLA-DR53 was 52 years old (P = 0.004), and amino acids (LLERRRA) of the HVR3-encoded immunodominant epitope of HLA-DR53 is mimicked by pathogenic viruses the homozygosity rates in patients below and above the median age were different (25.7 vs 5.2%, P = 0.003). The including EBV which plays a role in the pathogenesis of Hodgkin's disease. 12 For this reason and also to investigate the role study on CLL further confirmed the influence of the DR53 homozygosity (corresponding figures being 18.6 vs 2.9%, of HLA-DR53 in another hemopoietic malignancy, we initiated a study on Hodgkin's disease. As clearly stated in our P = 0.03), and also showed the protective (delaying) effect of homozygosity for HLA-DR52. 6 The mean ages of patients with original communication, we only have 'preliminary data' that appeared as an 'abstract'. We have reported that in the class II CLL homozygous for DR53 and DR52 are 54.8 ± s.e. 3.7 vs 65.8 ± s.e. 2.8 years (P = 0.02; two-tailed t-test), respectively. region, there was no significant association even with the early-onset group. A detailed analysis of the patients homoThe corresponding figures in the CML group are 32.1 ± s.e. 3.1 vs 49.4 ± s.e. 5.0 years (P = 0.007). The overall age distrizygous for HLA-DR53 showed that seven of the eight patients with this genotype were under the median age (P = 0.06) and butions of these two groups of patients are also significantly different by the log-rank test both in CLL (P = 0.04) and CML the oldest patient homozygous for DR53 was 46 years old (P = 0.04). We now have more samples and are still collecting (P = 0.01). These significant observations are strikingly similar to those made by Lilly et al 9 in their original study on mice. consecutive patients' samples. The results will be presented when the study is complete. In a congenic mouse model, they showed the influence of the two homozygous genotypes (namely H-2 k and H-2 b ) on the We will not be surprised if Hodgkin's disease has the same association with HLA as other major hemopoietic maligrate of development of both virus-induced and spontaneous leukemia. Unlike homozygosity, heterozygosity for H-2 k did nancies despite their very different etiologies. Because HLA has no primary role in the etiology of these diseases, a certain not accelerate the development of leukemia. It has to be noted that H-2 k and HLA-DR53 are serologically cross-reactive,
HLA and Hodgkin's disease: reply to Dorak et al
We stand by our original comments, and urge Dorak et al to GM Taylor Immunogenetics Laboratory DA Gokhale Dept of Medical Genetics publish their findings in Hodgkin's disease so that these can be tested by others.
St Mary's Hospital University of Manchester, UK
Unusual cytogenetic evolution in CML treated with interferon-␣
We read the article on aberrant cytogenetic evolution pattern or exacerbate immune-mediated complications, such as thyroid dysfunction, vasculitis, etc. ance with Johansson's results. Moreover these secondary aberInterferon has the potential to induce lasting complete or rations involved largely chromosome 3 (five cases), 9 (two major cytogenetic remissions in 20 to 30% of patients with cases) and 18 (two cases) associated with chromosome Ph1 chronic-phase Ph1-positive CML and has prompted a large and occurred in two patients in chronic phase. The analysis number of clinical trials. Cytogenetic response increased the of data from Johansson et al and our own shows a high inciduration of chronic phase and survival of the responding dence of cytogenetic alterations of chromosome 3 (11 cases patients.
2 Despite limited knowledge regarding the pharmacoover 42). Most of these concerned the long arm between q21 logic mechanisms by which IFN induces the unpredictable and q27 which is the locus of genes involved in leukemogencytogenetic response in CML, this therapy becomes standard esis such as the ecotropic virus integration 1 gene in acute therapy for patients with newly diagnosed CML. However, myeloid leukemia and myelodysplasia. We hypothesize that interferon produces side-effects that are usually dose-depen-IFN directly or indirectly induces a specific break on the long dent, such as flu-like symptoms, persistent fatigue, weight loss, arm of chromosome 3. However, what is the importance of depression and insomnia. Moreover, interferon-␣ can produce dose and duration of treatment with IFN? Some cytogenetic aberrations such as del(5), del(7), del(9) or −X are noted in myelodysplasia and suggest such an evol-
